Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 8/20 | 0.59 |
| ▸ | RAB9A | P51151 | 8/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.59 |
| ▸ | HPGD | P15428 | 4/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.59 |
| ▸ | NFKB2 | Q00653 | 3/20 | 0.59 |
| ▸ | RELA | Q04206 | 3/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.59 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.59 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | BCHE | P06276 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 2/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6483534 | 0.82 | RAB9A (0.64) | NPC1RAB9ASMN1; SMN2HPGDALDH1A1 | |
| SCHEMBL10870160 | 0.81 | RAB9A (0.54) | NPC1RAB9ASMN1; SMN2HPGDALDH1A1 | |
| SCHEMBL10333625 | 0.80 | NPC1 (0.61) | NPC1RAB9ASMN1; SMN2HPGDALDH1A1 | |
| Water SCHEMBL6475896 | 0.80 | NPC1 (0.61) | NPC1RAB9ASMN1; SMN2HPGDALDH1A1 | |
| Water SCHEMBL6475900 | 0.80 | NPC1 (0.61) | NPC1RAB9ASMN1; SMN2HPGDALDH1A1 | |
| SCHEMBL10333179 | 0.76 | CYP1A2 (0.64) | NPC1RAB9ASMN1; SMN2HPGDALDH1A1 | |
| SCHEMBL9678196 | 0.76 | SMN1; SMN2 (0.59) | NPC1RAB9ASMN1; SMN2HPGDALDH1A1 | |
| SCHEMBL10915532 | 0.76 | RAB9A (0.53) | NPC1RAB9ASMN1; SMN2HPGDALDH1A1 | |
| SCHEMBL9695295 | 0.75 | TP53 (0.67) | NPC1RAB9ASMN1; SMN2HPGDALDH1A1 | |
| SCHEMBL9678752 | 0.74 | RAB9A (0.61) | NPC1RAB9ASMN1; SMN2HPGDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6906078-B2 | Method of using (H+/K+) ATPase inhibitors as antiviral agents | PHARMACIA CORPORATION (US) | 2005-06-14 | — | — | US | disclosed |
| US-20010047038-A1 | Method of using (H+/K+) ATPase inhibitors as antiviral agents | MOORMAN ALAN E (US) | 2001-11-29 | — | — | US | disclosed |
| US-5945425-A | ADENOSINE TRIPHOSPHASE INHIBITOR; DNA VIRICIDE | G.D. SEARLE & CO. (US) | 1999-08-31 | — | — | US | disclosed |
| US-4772619-A | ANTIULCER AGENTS | G. D. SEARLE & CO. (US) | 1988-09-20 | — | — | US | disclosed |
| EP-0174717-A1 | Benzimidazoles, and their production formulation and use as gastric acid secretion inhibitors | FISONS plc (GB) | 1986-03-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010047038-A1 | Method of using (H+/K+) ATPase inhibitors as antiviral agents | ATP4A, ATP1A1, ATP1A4 | NPC1 363/4885RAB9A 486/4885SMN1; SMN2 4616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.